IP protection, page-6

Post #: 75360924

G'day @reon1

This will give you some good background: https://pharmaust.com/rm-capital-2/

Ignore the valuations and a lot of the commentary as it is way out of date, but the summary of the IP that begins on p.8 remains useful.

The IP has progressed since then.

This is the second most recent grant (2018) but the most relevant for ND applications: https://patentimages.storage.googleapis.com/fa/91/ca/f4771f022ed151/US10053422.pdf
The breadth of this patent - 'mTOR pathway diseases' - is significant. It specifically identifies the use of MPL in ND (amongst other disease types).

There is also an application currently pending in PCT jurisdicitons that has entered the US national phase that aims to further strengthen the IP position: https://patentimages.storage.googleapis.com/46/6b/cc/5e0778e29e11ce/US20230181516A1.pdf

The most recent aplication was filed in AU in July this year (so the application hasn't been published yet) but the name tells you that it provides methods for the poroduciton of MPL: https://ipsearch.ipaustralia.gov.au/patents/2024902063

In a nutshell, we don't own the molecule (the composition of matter patent) but we do own the methods of use for that molecule in a broad range of diseases.

Happy reading.

Cheers

Densy